ANKE BIO(SZ:300009) Xin Lang Cai Jing·2025-11-07 02:17Core Viewpoint - Anke Biological has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but a decline in net profit for the recent period [1][2]. Financial Performance - As of October 31, Anke Biological reported a revenue of 1.963 billion yuan for the period from January to September 2025, representing a year-on-year growth of 2.15%. However, the net profit attributable to shareholders was 551 million yuan, which reflects a decrease of 6.48% compared to the previous year [2]. - The company has cumulatively distributed 2.662 billion yuan in dividends since its A-share listing, with 1.252 billion yuan distributed over the last three years [3]. Stock Market Activity - On November 7, Anke Biological's stock price increased by 2.06%, reaching 10.91 yuan per share, with a trading volume of approximately 90.89 million yuan and a turnover rate of 0.69%. The total market capitalization stood at 18.247 billion yuan [1]. - Year-to-date, the stock price has risen by 30.02%, with a slight increase of 5.72% over the past 20 trading days [1]. Shareholder Structure - As of September 30, 2025, Anke Biological had 76,900 shareholders, an increase of 4.63% from the previous period. The average number of circulating shares per shareholder decreased by 4.43% to 15,886 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 19.5226 million shares, a decrease of 1.269 million shares from the previous period [3].